Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors

Journal of Receptors and Signal Transduction

Volumn 26, Issue 1-2, 2006, Pages 107-128

  Schwartz, Thue W ^a,b   Holst, Birgitte ^a  

^a 7TM Pharma A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Artificial sweetener; Calcium sensor; Cinecalcet; Cyclamate; G protein coupled receptor; GABA receptor; Ghrelin receptor; Glycoprotein hormone receptor; GPCR; MC1 receptor; MC4 receptor; Melanocortin receptor; Taste receptor; TSH receptor; Umami receptor; Zinc ion

Indexed keywords

3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ANTINEOPLASTIC AGENT; CALCIMIMETIC AGENT; CGP 7930; CINACALCET; GHRELIN RECEPTOR; GHRELIN RECEPTOR AGONIST; GROWTH HORMONE SECRETAGOGUE; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IBUTAMOREN; MELANOCORTIN 1 RECEPTOR; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG; ZINC;

AGONIST; ALLOSTERISM; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; LIGAND BINDING; MOLECULAR MODEL; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALLOSTERIC REGULATION; ANIMALS; DIMERIZATION; HUMANS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RECEPTORS, CALCIUM-SENSING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 33645796458     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890600567570     Document Type: Review

References (49)

1. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002, 54, 323-374.
2. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 2003, 55, 597-606.
3. May LT, Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 2003, 3, 551-556.
4. Bruns RF, Fergus JH. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharm 1990, 38, 939-949.
5. Gao ZG, Van Muijlwijk-Koezen JE, Chen A, Muller CE, Ijzerman AP, Jacobson KA. Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol 2001 60, 1057-1063.
6. Clark AL, Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 1976, 58, 323-331.
7. Birdsall NJ, Cohen F, Lazareno S, Matsui H. Allosteric regulation of G-protein-linked receptors. Biochem Soc Trans 1995, 23, 108-111.
8. Pin JP, Kniazeff J, Liu J, et al. Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 2005, 272, 2947-2955.
9. Nemeth EF. Calcimimetic and calcilytic drugs: just for parathyroid cells? Cell Calcium 2004, 35, 283-289.
10. Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 2002, 8, 2077-2087.
11. Jakubik J, Bacakova L, Lisa V, El-Fakahany EE, Tucek S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci USA 1996, 93, 8705-8709.
12. Thomas EA, Carson MJ, Neal MJ, Sutcliffe JG. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci USA 1997, 94, 14115-14119.
13. Kinney GG, O'Brien JA, Lemaire W, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005, 313, 199-206.
14. Holst B, Elling CE, Schwartz TW. Metal-ion mediated agonism and agonist-enhancement in the melanocortin MC1 and MC4 receptors. J Biol Chem 2002, 277, 47662-47670.
15. Binet V, Brajon C, Le Corre L, Acher F, Pin JP, Prezeau L. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J Biol Chem 2004, 279, 29085-29091.
16. Holst B, Brandt E, Bach A, Heding A, Schwartz TW. Non-peptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol 2005, 19, 2400-2411.
17. Urwyler S, Mosbacher J, Lingenhoehl K, et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001, 60, 963-971.
18. Kenakin TP. Pharmacologic Analysis of Drug-Receptor Interactions. New York: Raven Press, 1993.
19. Monod J, Wyman J, Changeux JP. On the nature of allosteric transitions: A plausible model. J Mol Biol 1965, 12, 88-118.
20. Koshland DE, Jr. Nemethy G, Filmer D. Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 1966, 5, 365-385.
21. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2001, 2, 274-286.
22. White JH, Wise A, Main MJ, et al. Heterodimerization is required for the formation of a functional GABAB receptor. Nature 1998, 396, 679-682.
23. Kuner R, Kohr G, Grunewald S, Eisenhardt G, Bach A, Kornau HC. Role of heteromer formation in GABAB receptor function. Science 1999, 283, 74-77.
24. Terrillon S, Durroux T, Mouillac B, et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 2003, 17, 677-691.
25. Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 2004, 5, 30-34.
26. Baneres JL, Parello J. Structure-based analysis of GPCR function: Evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J Mol Biol 2003, 329, 815-829.
27. El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, Parmentier M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 2005, 67, 460-469.
28. Urizar E, Montanelli L, Loy T, et al. Glycoprotein hormone receptors: Link between receptor homodimerization and negative cooperativity. EMBO J 2005, 24, 1954-1964.
29. Mesnier D, Baneres JL. Cooperative conformational changes in a G-protein-coupled receptor dimer, the leukotriene B(4) receptor BLT1. J Biol Chem 2004, 279, 49664-49670.
30. Wreggett KA, Wells JW. Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J Biol Chem 1995, 270, 22488-22499.
31. Chidiac P, Green MA, Pawagi AB, Wells JW. Cardiac muscarinic receptors. Cooperativity as the basis for multiple states of affinity. Biochemistry 1997, 36, 7361-7379.
32. Sinkins WG, Kandel M, Kandel SI, Schunack W, Wells JW. G protein-linked receptors labeled by [3H]histamine in guinea pig cerebral cortex. I. Pharmacological characterization [corrected]. Mol Pharmacol 1993, 43, 569-582.
33. Rosenkilde MM, Lucibello M, Holst B, Schwartz TW. Natural agonist enhancing bis-His zinc-site in transmembrane segment V of the tachykinin NK3 receptor. FEBS Lett 1998, 439, 35-40.
34. Pin JP, Kniazeff J, Binet V, et al. Activation mechanism of the heterodimeric GABA(B) receptor. Biochem Pharmacol 2004, 68, 1565-1572.
35. Jiang P, Cui M, Zhao B, et al. Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste. J Biol Chem 2005, 280, 15238-15246.
36. Xu H, Staszewski L, Tang H, Adler E, Zoller M, Li X. Different functional roles of T1R subunits in the heteromeric taste receptors. Proc Natl Acad Sci USA 2004, 101, 14258-14263.
37. Birdsall NJ, Lazareno S, Popham A, Saldanha J. Multiple allosteric sites on muscarinic receptors. Life Sci 2001, 68, 2517-2524.
38. Lazareno S, Popham A, Birdsall NJ. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol 2002, 62, 1492-1505.
39. Trankle C, Weyand O, Voigtlander U, et al. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol 2003, 64, 180-190.
40. Feighner SD, Howard AD, Prendergast K, et al. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol 1998; 12, 137-145.
41. Kniazeff J, Bessis AS, Maurel D, Ansanay H, Prezeau L, Pin JP. Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat Struct Mol Biol 2004, 11, 706-713.
42. Hofmann KP. Signalling states of photoactivated rhodopsin. Novartis Found Symp 1999, 224, 158-175.
43. Hlavackova V, Goudet C, Kniazeff J, et al. Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J 2005, 24, 499-509.
44. Durroux T. Principles: A model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends Pharmacol Sci 2005, 26, 376-384.
45. Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001, 86, 1116-1125.
46. Bach MA, Rockwood K, Zetterberg C, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 2004, 52, 516-523.
47. Laferrere B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 2005, 90, 611-614.
48. Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab 2003, 16, 981-985.
49. Svensson J, Ohlsson C, Jansson JO, et al. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res 1998, 13, 1158-1166.